A comparative pharmacodynamic study of ticagrelor versus clopidogrel and ticagrelor in patients undergoing primary percutaneous coronary intervention: The CAPITAL RELOAD study

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Hibbert, Benjamin ^a   Maze, Ronnen ^a   Pourdjabbar, Ali ^a   Simard, Trevor ^a   Ramirez, F Daniel ^a   Moudgil, Rohit ^a   Blondeau, Melissa ^a   Labinaz, Marino ^a   Dick, Alexander ^a   Glover, Christopher ^a   Froeschl, Michael ^a   Marquis, Jean François ^a   So, Derek Y F ^a   Le May, Michel R ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; HIRULOG; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; ADENOSINE; TICLOPIDINE;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOGENIC SHOCK; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY CIRCUMFLEX BRANCH; DOOR TO BALLOON; DRUG BIOAVAILABILITY; DRUG EFFECT; FEMALE; HUMAN; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PROSPECTIVE STUDY; RIGHT CORONARY ARTERY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT; THROMBOCYTE FUNCTION; TIME; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG EFFECTS; MIDDLE AGED; THROMBOCYTE;

ADENOSINE; BLOOD PLATELETS; FEMALE; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; TICLOPIDINE;

EID: 84908480624     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092078     Document Type: Article

References (29)

1. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, et al. (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361: 1045-1057.
2. Steg PG, James S, Harrington RA, Ardissino D, Becker RC, et al. (2010) Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 122: 2131-2141.
3. O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Jr., Chung MK, et al. (2013) 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 127: 529-555.
4. Bell AD, Roussin A, Cartier R, Chan WS, Douketis JD, et al. (2011) The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society Guidelines Executive Summary. Can J Cardiol 27: 208-221.
5. Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, et al. (2013) Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 62: 2261-2273.
6. Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, et al. (2011) Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 124: 1132-1137.
7. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, et al. (2006) Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 27: 1038-1047.
8. Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, et al. (2012) Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 5: 797-804.
9. Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, et al. (2013) Comparison of Prasugrel and Ticagrelor Loading Doses in ST-Segment Elevation Myocardial Infarction Patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) Primary PCI Study. J Am Coll Cardiol 61: 1601-1606.
10. Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, et al. (2010) Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 121: 1188-1199.
11. Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, et al. (2007) Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 50: 1844-1851. (Pubitemid 350007959)
12. Husted S, van Giezen JJ (2009) Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther 27: 259-274.
13. Le May MR, Wells GA, So DY, Glover CA, Froeschl M, et al. (2012) Reduction in mortality as a result of direct transport from the field to a receiving center for primary percutaneous coronary intervention. J Am Coll Cardiol 60: 1223-1230.
14. Hibbert B, Macdougall A, Labinaz M, O'Brien ER, So DY, et al. (2012) Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry. Circ Cardiovasc Interv 5: 805-812.
15. Le May MR, So DY, Dionne R, Glover CA, Froeschl MP, et al. (2008) A citywide protocol for primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 358: 231-240.
16. Haase J, Bayar R, Hackenbroch M, Storger H, Hofmann M, et al. (2004) Relationship between size of myocardial infarctions assessed by delayed contrast-enhanced MRI after primary PCI, biochemical markers, and time to intervention. J Interv Cardiol 17: 367-373. (Pubitemid 39552591)
17. Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, et al. (2007) Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 50: 1852-1856. (Pubitemid 350017792)
18. Heestermans AA, van Werkum JW, Taubert D, Seesing TH, von BN, et al. (2008) Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res 122: 776-781.
19. Ravnefjord A, Weilitz J, Emanuelsson BM, van Giezen JJ (2012) Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model. Thromb Res 130: 622-628.
20. Brar SS, ten BJ, Marcucci R, Price MJ, Valgimigli M, et al. (2011) Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 58: 1945-1954.
21. Patti G, Nusca A, Mangiacapra F, Gatto L, D'Ambrosio A, et al. (2008) Point-ofcare measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 52: 1128-1133.
22. Collet JP, Cuisset T, Range G, Cayla G, Elhadad S, et al. (2012) Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 367: 2100-2109.
23. Alexopoulos D, Dimitropoulos G, Davlouros P, Xanthopoulou I, Kassimis G, et al. (2011) Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping. JACC Cardiovasc Interv 4: 403-410.
24. Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, et al. (2012) Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol 60: 193-199.
25. Roberts JD, Wells GA, Le May MR, Labinaz M, Glover C, et al. (2012) Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 379: 1705-1711.
26. Bliden KP, Tantry US, Storey RF, Jeong YH, Gesheff M, et al. (2011) The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies. Am Heart J 162: 160-165.
27. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T,et al. (2009) Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120: 2577-2585.
28. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, et al. (2010) Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303: 754-762.
29. Siller-Matula JM, Trenk D, Schror K, Gawaz M, Kristensen SD, et al. (2013) Response variability to P2Y12 receptor inhibitors: expectations and reality. JACC Cardiovasc Interv 6: 1111-1128.